- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04186507
Indirect Evaluation of Lithium Level in Blood Using Non-invasive Sweat Biosensors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Lithium (Li+) is one of the most widely used and studied medications for treating of Bipolar Mood Disorder, resistant cases of Major Psychiatric Disorders and especially Major Depressive Disorder.
After administration, more than 95% of administered dose of Li+ is eliminated unchanged in the urine, less than 5% - in the saliva, sweat, and feces. Up to 40% of patients that are on Li+ therapy encounter adverse effects that can be explained by drug involvement in various biochemical processes. Li+ efficacy and side effect manifestation are obviously determined by the drug concentration in blood. The optimal way to prevent manifestation of side effects is to control that Li+ serum level is within therapeutic range. A blood test is often ordered to monitor the serum level of Li+ to ensure target serum levels are reached. The available methods for blood Li+ are invasive, time consuming, and cause of discomfort for patients, yet are of a great importance as levels of drug in blood outside the therapeutic range may dramatically affect patient health. It is especially of importance for Li+ treatments it has a narrow therapeutic window - 0.6-1.5 mmol/L. Thus, there is a growing need for a reliable, comfortable, and inexpensive method for detection of Li+ in blood that can be performed easily in an in-patient setting and automatically whenever necessary without the need for a clinic visit out-patient setting.
Spectrophon LTD has developed an algorithm that allows calculation of levels of various compounds contained in sweat using standard PPG sensors with special coating and thus to estimate the levels of corresponding chemicals in the bloodstream. This algorithm has proven useful and accurate in clinical trials on detection of dehydration level, blood sodium level, and blood glucose level. We suggest that Spectrophon biosensors can be used to detect the levels of Li+ in sweat that will allow non-invasive estimation of the level of corresponding medication in blood in real-time.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Haifa
-
Tirat Karmel, Haifa, Israel, 30200
- Tirat Carmel Mental Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Meeting Diagnostic and Statistical Manual 5th edition (DSM-V) criteria for MDD, BMD, Schizoaffective Disorder, Schizophrenia;
- Patients must be on constant Li+ treatment or prior their first drug administration.
- Ability and willingness to sign an informed consent form for participation in the study.
Exclusion Criteria:
- Evidence of serious disorder;
- Unstable chronic disease;
- Kidney disease
- Pregnancy;
- Contraindication for Li+ treatment.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prelaminary group
To confirm that Li+ is detectable in sweat .
|
|
Spectrophon LTD biosensors for Li+ detection in sweat
In this group will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat
|
To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection. Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels. To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood. To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat. Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lithium sweat concentration
Time Frame: 6 month
|
Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD) will be placed on the right wrist of each participant for a non-invasive measurement of blood Li+ level.
|
6 month
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- TiratCarmelMHC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lithium Level Detection in Sweat
-
Ramathibodi HospitalCompletedChange in Serum Chloride Level
-
University Hospital, Basel, SwitzerlandCompleted
-
Loyola UniversityCompletedPreferred Level of Involvement in Decision MakingUnited States
-
PepsiCo Global R&DCompletedFluid Intake in Athletes | Sweating Rate in Athletes | Sweat Chloride Concentration in AthletesUnited States
-
V.A. Nasonova Research Institute of Rheumatology...AstraZenecaNot yet recruitingElevated Level of IFN Type I in SLE Patients
-
USDA, Western Human Nutrition Research CenterUniversity of California, DavisCompletedStability & Variability of Lipid-derived Molecules in SweatUnited States
-
Korea UniversityCompletedsRAGE Level | SUV and TBR Levels in FDG PET
-
Ozden GokcekCompletedPhysical Activity Level | Use of a Walker in Infancy | Musculoskeletal ProblemsTurkey
-
Fayoum UniversityUnknownCompare Serum Level of Klotho in Patients on Oral Antidiabetic TreatmentEgypt
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Etablissement... and other collaboratorsRecruitingThe Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy VolunteersFrance